Abstract
Currently available antiepileptic drugs (AEDs) were developed to suppress seizure activity but less for prevention of epileptogenesis or for treatment of epileptogenic encephalopathies. Despite considerable efforts towards pharmacological control of seizures, about 30 % of epileptic patients do not achieve complete seizure control, and these numbers are even higher in patients suffering from partial seizures - a common form of epilepsy in adults. The mechanisms behind drug-resistance are far from being understood. Likely several unrelated mechanisms might lead in concert to reduced efficacy of the AEDs. Consequently, there is a need for predictive biomarkers of susceptibility to pharmacoresistant seizures and for new therapies interfering with epileptogenesis and preventing development of drug-resistance instead of merely suppressing seizures. This also necessitates the design of novel in vitro and in vivo epilepsy models that would better mimic the progressive nature of epilepsy and resemble the state of a chronic epileptic tissue. In this review we discuss current theories of drug-resistance and give a short summary of the epilepsy models that are frequently used for testing AEDs. We will also highlight caveats of the different models and consider novel approaches to overcome these difficulties. Finally we give a short outlook on unconventional therapies interfering with epileptogenesis as well as with drug delivery and retention.
Keywords: Blood-brain barrier, brain slices, electrical kindling, kainate, multidrug transporter, neuroinflammation, pharmacoresistance, pilocarpine, slice cultures, temporal lobe epilepsy.
Current Medicinal Chemistry
Title:Models in Research of Pharmacoresistant Epilepsy: Present and Future in Development of Antiepileptic Drugs
Volume: 21 Issue: 6
Author(s): R. Kovacs and U. Heinemann
Affiliation:
Keywords: Blood-brain barrier, brain slices, electrical kindling, kainate, multidrug transporter, neuroinflammation, pharmacoresistance, pilocarpine, slice cultures, temporal lobe epilepsy.
Abstract: Currently available antiepileptic drugs (AEDs) were developed to suppress seizure activity but less for prevention of epileptogenesis or for treatment of epileptogenic encephalopathies. Despite considerable efforts towards pharmacological control of seizures, about 30 % of epileptic patients do not achieve complete seizure control, and these numbers are even higher in patients suffering from partial seizures - a common form of epilepsy in adults. The mechanisms behind drug-resistance are far from being understood. Likely several unrelated mechanisms might lead in concert to reduced efficacy of the AEDs. Consequently, there is a need for predictive biomarkers of susceptibility to pharmacoresistant seizures and for new therapies interfering with epileptogenesis and preventing development of drug-resistance instead of merely suppressing seizures. This also necessitates the design of novel in vitro and in vivo epilepsy models that would better mimic the progressive nature of epilepsy and resemble the state of a chronic epileptic tissue. In this review we discuss current theories of drug-resistance and give a short summary of the epilepsy models that are frequently used for testing AEDs. We will also highlight caveats of the different models and consider novel approaches to overcome these difficulties. Finally we give a short outlook on unconventional therapies interfering with epileptogenesis as well as with drug delivery and retention.
Export Options
About this article
Cite this article as:
Kovacs R. and Heinemann U., Models in Research of Pharmacoresistant Epilepsy: Present and Future in Development of Antiepileptic Drugs, Current Medicinal Chemistry 2014; 21 (6) . https://dx.doi.org/10.2174/0929867320666131119152613
DOI https://dx.doi.org/10.2174/0929867320666131119152613 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Roles of TRAF6 in Central Nervous System
Current Neuropharmacology Molecular Therapeutics of HBV
Current Gene Therapy The Control of Male Sexual Responses
Current Pharmaceutical Design Voltage-Gated Sodium Channel Blockers; Target Validation and Therapeutic Potential
Current Topics in Medicinal Chemistry Preclinical Profile of Bacopasides From Bacopa monnieri (BM) As An Emerging Class of Therapeutics for Management of Chronic Pains
Current Medicinal Chemistry Epilepsy, Comorbidities and Treatments
Current Pharmaceutical Design Madecassic Acid Reduces Fast Transient Potassium Channels and Promotes Neurite Elongation in Hippocampal CA1 Neurons
CNS & Neurological Disorders - Drug Targets Adiponectin and its Role in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets The Changing Landscape of Voltage-Gated Calcium Channels in Neurovascular Disorders and in Neurodegenerative Diseases
Current Neuropharmacology Flavonoids and other Non-alkaloidal Constituents of Genus Erythrina: Phytochemical Review
Combinatorial Chemistry & High Throughput Screening Hepatocyte Growth Factor (HGF): Neurotrophic Functions and Therapeutic Implications for Neuronal Injury/Diseases
Current Signal Transduction Therapy Cytotoxicity and Anti-proliferative Properties of Heterocyclic Compounds Derived from Progesterone
Anti-Cancer Agents in Medicinal Chemistry CB1 Cannabinoid Receptors and their Associated Proteins
Current Medicinal Chemistry PDZ Domain-mediated Protein Interactions: Therapeutic Targets in Neurological Disorders
Current Medicinal Chemistry FMRI of the Emotions: Towards an Improved Understanding of Amygdala Function
Current Medical Imaging Statins in the Treatment of Acute Ischemic Stroke
Current Pharmaceutical Biotechnology Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?
Current Pharmaceutical Design Ketogenic Diets in the Treatment of Epilepsy
Current Pharmaceutical Design HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets The Ubiquitous Choline Transporter SLC44A1
Central Nervous System Agents in Medicinal Chemistry